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ABSTRACT          20 
The insidious nature of Zika virus (ZIKV) infections can have a devastating consequence for 21 
foetal development.  Recent reports have highlighted that chloroquine (CQ) is capable of 22 
inhibiting ZIKV endocytosis in brain cells.  We applied pharmacokinetic modelling to 23 
develop a predictive model for CQ exposure to identify an optimal maternal/foetal dosing 24 
regimen to prevent ZIKV endocytosis in brain cells.  Model validation utilised 13 non-25 
pregnancy and 3 pregnancy clinical studies and a therapeutic CQ plasma window of 0.3-2 26 
µM was derived. Dosing regimens used in rheumatoid arthritis, systemic lupus erythematosus 27 
and malaria were assessed for their ability to target this window.  Dosing regimen identified 28 
that weekly doses used in malaria were not sufficient to reach the lower therapeutic window, 29 
however daily doses of 150 mg achieved this therapeutic window. The impact of gestational 30 
age was further assessed and culminated in a final proposed regimen of 600 mg on day 1, 300 31 
mg on day 2 and 3 and 150 mg thereafter until the end of trimester 2, which resulted in 32 
maintaining 65 % and 94 % of subjects with a trough plasma concentration above the lower 33 
therapeutic window on day 6 and at term, respectively. 34 
  35 
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1. INTRODUCTION 39 
First isolated in an infected Ugandan monkey in 1947 
1
, the Zika virus (ZIKV), is a single 40 
stranded RNA virus originating from the Flaviviridae family and is transmitted to its host 41 
through bites from various Aedes species mosquito.  Other members of the Flaviviridae 42 
family include West Nile virus, dengue and yellow fever 
2
. An epidemic of Zika broke out in 43 
the Yap Islands in 2007 and was later known to have been reported in French Polynesia 44 
between 2013 and 2014, followed by a spread to the Americas in 2015 
1,3
 and subsequently 45 
countries from Africa, Asia and the Pacific 
3
.  The Pan American Health Organisation 46 
(PAHO) and the World Health Organisation (WHO) reports that, aside from the States within 47 
the USA, 48 other Central and South American countries have now become affected by the 48 
transmission of the disease, and there have been a total of 3720 cases of congenital syndrome 49 
associated with the infection 
4
.  The impact of ZIKV on foetal development can be described 50 
by five comment features: (i) severe microcephaly, (ii) reduced brain tissue, (iii) ocular 51 
damage, (iv) congenital contractures and (v) hypertonia restricting body movements 
5
.  The 52 
South American country of Brazil has particularly been affected by the largest number of 53 
congenital syndrome cases associated with ZIKV, currently 2952 confirmed cases (4
th
 54 
January 2018) 
4,6
 
7,8
.  With cases reported in several countries across the world, the spread of 55 
ZIKV disease may now be referred to as a pandemic 
1
. 56 
ZIKV has an incubation period thought to be between 3 and 12 days. A key symptom of the 57 
disease is a maculopapular rash in the face, palm, sole and trunk which is expected to be seen 58 
within the seven days of infection and infection may last for weeks. Other symptoms of the 59 
disease include the fever, joint pain, conjunctivitis and retroocular headache and usually 60 
resolves in one week 
9-11
.  However, acute inflammatory polyradiculoneuropathy known as 61 
the Guillian-Barre syndrome, is a complication and can consequently cause weakness and 62 
reduced reflexes in victims 
9,11
. Further, ZIKV is capable of crossing the placenta and brings 63 
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about congenital anomalies such as microcephaly and other ophthalmologic abnormalities in 64 
the foetus. ZIKV strains has been found to be present in the placenta and foetal tissue as well 65 
as the amniotic fluid of mothers with new-borns 
6,8,12-16
. Therefore, a major concern for ZIKV 66 
infections is the progression of the virus towards into foetal tissue and the subsequent 67 
devastating consequences on foetal brain development. 68 
Currently there are no viable treatment options to prevent the spread of ZIKV.  However, in a 69 
study by Delvecchio et al (2016) 
17
, the potential for the antimalarial agent chloroquine (CQ) 70 
to inhibit the endocytosis of ZIKV within human brain microvascular endothelial and neural 71 
stem cells was demonstrated in-vitro.  Chloroquine has been approved by the Food and Drug 72 
Administration (FDA) for the treatment of malaria and for prophylactic treatment in pregnant 73 
women at risk of Plasmodium parasites 
18
. In addition to its antimalarial benefits, CQ has 74 
been used as a suppressant of autoimmune disorders such as rheumatoid arthritis (RA) and 75 
systemic lupus erythematosus (SLE) 
19
.  Further, CQ has been demonstrated to prevent the 76 
pH-dependant steps in viral replications for human HIV 
20
, human influenza A, 
21
 Japanese 77 
encephalitis virus 
22
 and dengue virus type 2 
23
.  Given that CQ is widely used in non-78 
pregnant and pregnant subjects for a range of therapeutic interventions, it represents a viable 79 
candidate for the potential repurposing in the prevention of ZIKV disease, particularly prior 80 
to and during pregnancy.  Further, any potential teratogenic risk associated with CQ use in 81 
pregnancy has been investigated  at doses used for malaria, SLE and RA 
18
. Wolfe et al. 82 
(1985) 
24
 demonstrated no significant teratogenic consequences of CQ in pregnant women in 83 
169 births from women who had received 300 mg weekly of chloroquine for malaria during 84 
their pregnancy.  In a further study, Levy et al (1991) 
18
 demonstrated that infants born to the 85 
majority of pregnant women being treated with CQ for RA and SLE, who received up to 250 86 
mg of CQ salt daily in the first trimester or 500 mg CQ salt daily for three days during early 87 
pregnancy, did not develop adverse conditions likely to be related to the use of CQ in their 88 
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mothers.  Furthermore, Mackenzie et al (1983) 
25
 demonstrated no retinal damage associated 89 
with CQ in 900 SLE patients (non-pregnant) who were treated with less than 4 mg/kg/day of 90 
CQ salt, and suggested that the threshold for ocular toxicity was 5.1 mg/kg/day 
25
.  Finally, 91 
although very few studies have examined foetal CQ pharmacokinetics, two separate studies, 92 
Law et al (2008) 
26
 and Akintonwa et al (1998) 
27
, reported the CQ ratio between the foetal 93 
cord concentrations and the maternal plasma concentrations (C:M ratio) as being 94 
approximately 1, suggesting that the placenta is not a major barrier to the partitioning of CQ 95 
into the foetus and that maternal plasma concentrations would be similar to those exposed to 96 
the foetus.  97 
Despite being used worldwide for over half of a century for anti-malaria prophylaxis 
28,29
, 98 
there has been no significant evidence suggesting foetal damage caused from the use of CQ 99 
in pregnant women 
30-33
, adding to the possibility of repurposing CQ for prevent of ZIKV 100 
endocytosis in the developing foetal brain. 101 
Given the distinct physiological changes occurring during gestation
34-37
, any attempt at 102 
providing potential doses for ZIKV during pregnancy should account for the subsequent 103 
alterations in CQ pharmacokinetics during each trimester. 104 
In this current study, a physiologically based pharmacokinetic (PBPK) model was developed 105 
to describe the deposition of CQ in non-pregnant and pregnant subjects, with a particular 106 
emphasis on: (i) identifying an appropriate plasma therapeutic window for ZIKV, (ii) 107 
optimising dosing regimens to attain this therapeutic window and (iii) assessing an optimal 108 
dosing regimen for use in different stages of gestation.  109 
2. METHODS 110 
The virtual clinical trial simulator Simcyp (Simcyp® Ltd, a Certara company, Sheffield, UK, 111 
Version 16) was used to create all the population based PBPK models used in this study 112 
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through the implementation of a pre-validated ‘Healthy Volunteer’ (HV) population.  For 113 
simulations requiring the use of pregnant subjects, we utilised the Simcyp ‘Pregnancy’ 114 
population group 
38-40
, which incorporates gestational-phase dependant physiological changes 115 
associated with pregnancy that may alter the pharmacokinetics of drugs such as a change in 116 
blood volume and organ/tissue blood flows; change in enzyme/protein expressions 
38,41-45
. 117 
A 3-stage workflow model was utilised and is detailed in Figure 1.  We adopted a robust 118 
validation approach utilising 16 clinical studies for CQ, a summary of which is described 119 
within the supplementary material (Section A, Table S1).  Further, unless otherwise stated, 120 
population sizes used in validation steps simulations and those utilised within Steps 3 121 
included a 10x10 trial design with 100 subjects. 122 
2.1 Step 1: Development and validation of a CQ model in non-pregnant subjects 123 
Model development utilised a total of 13 clinical studies reporting CQ pharmacokinetic 124 
across a range of Caucasian and non-Caucasian population groups (see Supplementary 125 
Materials: Section A).  These studies incorporated both single and multiple dose studies for 126 
CQ model development and validation.  CQ physicochemical parameters were obtained from 127 
published studies and are detailed in Table 1. During model development, where the model 128 
did not appropriately recover the shape of plasma concentration-time profile and/or 129 
pharmacokinetic parameters, a parameter estimation methodology was employed. Further 130 
details on validation and optimisation can be found in the Supplementary Materials: Section 131 
B. 132 
For clinical studies conducted in non-Caucasian populations (Filiopino, Papuan, Nigerian, 133 
Pakistani, and Thai), the Simcyp HV population group was adapted to incorporate 134 
appropriate age-body weight relationships reported in non-Caucasian subjects 
46
.  Adaptation 135 
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to the age-weight relationships for non-Caucasian populations are reported in Supplementary 136 
Materials: Section B. 137 
  138 
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2.2 Step 2: Development and validation of a CQ model in pregnant subjects 139 
For simulations involving pregnant women, the non-pregnant CQ model was revised to 140 
incorporate a full PBPK distribution model, which allows for consideration of gestation-141 
phase dependant changes in maternal physiology 
41,42,44,45
 for pharmacokinetic modelling 142 
studies 
38-40
. To recover the distribution phase profile, an appropriate volume of distribution 143 
(Vss) was empirically fixed at the mean of the range reported in literature studies utilising 144 
pregnant subjects 
31,32,47
, following by parameter estimation using a Weighted Least Square 145 
(WLS) method and the Nelder-Mead minimisation approach. Parameter estimates for the 146 
final optimised pregnancy model are detailed in Table 1. This optimised CQ model was 147 
subsequently validated utilising three clinical studies, details of which can be found in 148 
Supplementary Materials: Section C Table S2. 149 
2.3 Step 3: Identification of a suitable CQ prophylactic dose regimen for ZIKV  150 
In order to propose a plasma therapeutic window for CQ which could be used to identify an 151 
optimal dosing regimen against ZIKV, we utilised reported in vitro and in vivo concentrations 152 
for the inhibition of ZIKV into cells. Delvecchio et al. (2016) reported a CQ EC50 for the 153 
inhibition of ZIKV uptake within Vero cells, human brain microvascular endothelial cells 154 
(hBMEC) and human neural stem cells (hNSC) being within the range of 9-15 µM 
17
.  155 
Further, in ZIKV-infected interferon signalling-deficient AG129 mice, Shiryaev et al 156 
(2017) 
48
, reported that CQ extended their lifespan and confirmed that concentrations up to 40 157 
µM were able to reduce ZIKV uptake in primary human foetal neural progenitor cells (NPCs) 158 
(with 90 % inhibition at 6 µM).   159 
In other studies, the correlation between brain and plasma concentrations have been 160 
identified, with a suggested 10-to-30-fold greater brain concentration compared to plasma 161 
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concentrations for CQ 
49,50
 and a 4-to-30-fold difference for the CQ analogue 162 
hydroxychloroquine 
51
, highlighting the ability of CQ of adequately partition into brain tissue. 163 
Furthermore, in the study reported by Shiryaev et al (2017) 
48
, doses of 30 mg/kg were used 164 
in their ZIKV-infected interferon signalling-deficient AG129 mice to demonstrate uptake 165 
inhibition, this dose was similar to those used in arthritic patients where 5 mg/kg CQ salt 166 
was administered daily for one week which resulted in a CQ plasma concentrations of 10 167 
µM 
25
. A total dose of about of 30 mg/kg would be achieved in humans, which would 168 
comparable to doses used in the study by Shiryaev et al (2017) 
48
, suggesting that such 169 
plasma concentrations are attainable using similar dosing regimens employed for existing 170 
therapeutic indication for CQ. 171 
Therefore, in order to define a therapeutic window for CQ, we assumed that the target brain 172 
concentration of a maximum of 40 µM was required and to theoretically achieve this 173 
concentration in the human brain, a plasma concentration of less than an average of at least 174 
20-folds of the brain concentration may be requir d, that is, approximately 2 µM.  This was 175 
defined as the upper plasma therapeutic window. Given that concentration in excess of 6 µM 176 
have been reported to prevent ZIKV uptake in brain derived cells, we set the lower plasma 177 
therapeutic window at 20-fold less, that is 0.3 µM.  Therefore a plasma concentration 178 
therapeutic range of 0.3 µM to 2 µM was assumed in this study.  179 
To identify an appropriate dosing regimen to target this therapeutic window, plasma 180 
concentration-time profiles for CQ were simulated in 100 pregnant subjects (during the entire 181 
gestational phase of 280 days) using the validated CQ model at doses used for the 182 
prophylaxis of malaria and RA, i.e. 150 mg-300 mg weekly or 150 mg daily, respectively.   183 
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During this optimisation phase, the dose regimen which was able to maintain trough plasma 184 
concentrations above the lower limit of the plasma therapeutic window was identified as the 185 
optimal predicted dosing regimen. 186 
2.4 Predictive performance 187 
There are currently no universally agreed measure of predictive performance range when 188 
comparing observed data to predicted data in PBPK pharmacokinetic studies, however, a 2- 189 
fold prediction of observed data is largely accepted 
52-54
.  190 
2.5 Visual Predictive Checks 191 
Model predictions were compared to existing clinical studies using visual predictive checking 192 
(VPC), and approach described at the 2012 FDA Pediatric Advisory Committee (US Food 193 
and Drug Administration, 2012) 
55
. In brief, the predictability of the simulations was 194 
confirmed by comparing the predicted 5
th
 and 95
th
 percentiles of predicted concentration–195 
time profiles with the observed data for any validation data sets.  When the predicted data 196 
points overlapped with those from the observed data sets, which should (normally) contain a 197 
measure of spread of observed plasma concentration data (e.g., a standard deviation for each 198 
mean concentration point), the prediction was assumed to be valid. 199 
2.6 Data analysis 200 
Retrospective clinical data used for VPC were extracted using WebPlotDigitizer v.3.10 201 
(http://arohatgi.info/WebPlotDigitizer/).  Where applicable, statistical analysis was conducted 202 
using paired t-tests with a P < 0.05 indicating statistical significance. 203 
 204 
 205 
 206 
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3.  RESULTS    207 
3.1 Step 1: Development and validation of a CQ model in non-pregnant subjects 208 
Following the optimisation of the model, the final model predicted Cmax, AUC and tmax were 209 
within 2-fold of the reported parameters across all thirteen published single and multiple dose 210 
clinical studies in Caucasian and non-Caucasian subjects (Table 2).  Further, for these studies 211 
the model was able to appropriately recover the plasma concentration-time profiles (Figure 212 
2).  213 
The Mzayek et al (2007) 
56
 study demonstrated a wide variability in the absorption phase of 214 
the reported plasma concentration-time profiles, and the optimised model developed was able 215 
to recover this, with resultant predicted pharmacokinetic parameters within 2-fold of those 216 
reported (Table 2).  Further, for the Walker et al (1987) 
57
 study, the terminal elimination 217 
phase was slightly over predicted, however, the resultant AUC predicted by the model was 218 
within 2-fold of that reported (Table 2).  219 
3.2 Step 2: Development and validation of an optimised model of CQ in pregnant 220 
subjects  221 
The model was next optimised for use in pregnant population groups, utilising matching 222 
gestational weeks (where possible) to published studies, and subsequently was able to 223 
satisfactorily predict the plasma concentration-time profiles of CQ in pregnant women 224 
(Figure 4) with all pharmacokinetic parameters predicted to within 2-fold of those reported in 225 
clinical studies (Table 2). 226 
3.3 Step 3: Identification of a CQ prophylactic dosing regimen for ZIKV during 227 
pregnancy 228 
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In order to identify a dosing regimen appropriate for maintaining maternal plasma (and foetal 229 
exposure) levels, such that a sufficient concentration would be achieved to prevent foetal 230 
ZIKA brain endocytosis, standard CQ dosing regimens commonly used for malaria, RA and 231 
SLE (150 mg and 300 mg weekly, and 150 mg or 300 mg daily, respectively), were simulated 232 
during the first trimester.   233 
For malaria prophylaxis doses, 150 mg and 300 mg weekly, the simulated plasma 234 
concentration-time profiles did not achieve the lower target therapeutic limit until the end of 235 
trimester 1 (Supplementary Materials: Section C Figure S3) and were not considered for 236 
further optimisation. 237 
For doses used in RA and SLE, with a 150 mg daily dose the mean trough plasma-238 
concentration did not reach the lower limit of 0.3 µM until 12 days post first dose (Figure 239 
5A) where 96 % of subjects achieved a trough concentration in excess of the lower 240 
therapeutic window (Table 3).   At steady-state, a Cmax of 0.9 ± 0.4 µM was achieved.  For 241 
the 300 mg daily dose, the trough plasma-concentration doubled (Table 3) (Figure 5B), with a 242 
shortening of the time taken to reach the target plasma concentration to 5 days (Table 3).  243 
However, the mean steady-state Cmax was 1.8 ± 0.8 µM with 59 % of subject demonstrating a 244 
peak plasma-concentration in excess of 2 µM (Table 3) 245 
Dose optimisation was considered to identify an appropriate dosing regimen for trimester 1 to 246 
(i) achieve rapid attainment of the lower plasma therapeutic window and (ii) to maintain this 247 
concentration for the longest duration possible.  The dosing regimen identified was a loading 248 
dose of 600 mg on day 1 followed by 300 mg for 2 days and subsequently 150 mg daily 249 
during trimester 1 (Figure 5C). Under this regimen, the time taken for trough plasma 250 
concentration to be maintained within the therapeutic window shorted by six days (Figure 251 
5C) (Table 3) compared to a 150 mg daily dose (Figure 5A) (Table 3).  Further, only 1 % of 252 
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subjects possessed a plasma concentration above the upper therapeutic limit of 2 µM (Table 253 
3). 254 
 255 
Subsequently, the impact of initiating the optimal dosing regimen at the start of each 256 
trimester on the pharmacokinetics of CQ was assessed. CQ pharmacokinetic were simulated 257 
for each trimester period. In comparison to results from trimester 1, dosing this optimal 258 
regimen during either trimester 2 or 3 resulted in a progressive and statistically significant 259 
decrease (P < 0.001) in AUC, from 20.9 ± 9.6 µM.h to 11.8 ± 4.8 µM.h (calculated on the 260 
final day of the trimester) (Figure 6) with an increase in the time to reach target trough 261 
plasma concentration from 6 days for trimester 1 to 35 days for trimester 3 (Table 4) (Figure 262 
6).  Further, at trimester 3, only 79 % of subjects possessed a trough plasma concentration 263 
above the lower therapeutic limit (Table 4). 264 
 In order to finally identify an appropriate CQ dosing regimen for the entire duration of 265 
pregnancy, CQ treatment was extended from the end of the first trimester to the end of the 266 
second trimester. During trimester 1 (days 1 to 84), the predicted mean plasma concentration 267 
was maintained above the lower therapeutic window (Figure 7A) with a steady-state Cmax of 268 
0.92 ± 0.41 ng/mL (Table 5).  Assuming CQ was halted at the end of trimester 1, mean 269 
plasma concentration reached the lower therapeutic window on day 150 with 95 % of 270 
subjects possessing a trough plasma concentration above the lower therapeutic window 271 
(Table 5).  When dosing was continued throughout trimester 2 (Figure 7B), steady-state 272 
plasma concentrations were maintained with a Cmax of 0.92 ± 0.41 ng/mL (Table 5) until the 273 
end of trimester 2 (day 168), at which point CQ was halted.  Mean plasma concentrations 274 
reached the lower therapeutic window on day 279 with 94 % of subjects possessing a trough 275 
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plasma concentration above the lower therapeutic window and 5 % of subjects possessing a 276 
peak plasma concentration below the lower therapeutic window the (Table 5).  277 
 278 
 279 
4. DISCUSSION 280 
The Zika virus (ZIKV) is an infectious disease that began spreading at an alarming and 281 
unprecedented way in the early part of the current decade, and its spread has been classified 282 
as a pandemic 
1
.  Perhaps alarmingly (and importantly) a prominent feature of ZIKV which 283 
gained much publicity was the foetal and neurological consequences on infants born to 284 
infected mothers, and which primarily exhibited as microcephaly and Guillian-Barr 285 
syndrome.  Although no current treatment options are available for the prevention of the 286 
spread of ZIKV, the opportunity for repurposing existing treatments towards ZIKV exists for 287 
the antimalarial drug chloroquine (CQ).  This study addressed the potential to repurpose CQ 288 
for use in ZIKV, with a focus on developing potential dosing regimens for use in pregnancy.  289 
During model development and validation (Step 1), model performance depends largely upon 290 
the certainty of model input parameters describing CQ absorption, distribution and 291 
metabolism and elimination (ADME) 
58
.  When using literature reported pharmacokinetics 292 
parameters for absorption (ka), distribution (Vss) and elimination (clearance), the model 293 
performance was poor. This may be, in part, due to the wide variability reported for these 294 
parameters, for instance, ka has been reported in different studies as 1.8 h
-1
 (0.27-3.4 h
-1
) 
59
; 295 
1.19 h
-1 
± 1.44 h
-1 60
 and 0.51 h
-1
 ± 0.11 h
-1 61
 and Vss has been reported as 204-800 L/kg 
51
; 296 
128 L/kg (112-137 L/kg) 
47
 and 100-1000 L/kg 
62
.  Further, the reported Vss of CQ depends 297 
on whether they were estimated based on the plasma concentration or blood concentrations, 298 
particularly given that CQ has a high blood-to-plasma partitioning ratio of >5:1, therefore the 299 
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blood Vss is likely to differ from that of the plasma Vss by up to 10-folds 
63,64
. Therefore, we 300 
utilised a parameter estimation approach with the application of Weighted Least Square 301 
(WLS) and the Nelder-Mead minimisation, final optimised parameter value were obtained 302 
(Table 1), and this model was used for subsequently validation purposes.  303 
The application of this optimised model with retrospective clinical studies conducted in 304 
Caucasian subjects 
56,65,66
  resulted in model predictions of pharmacokinetic parameters to 305 
within 2-fold of that reports (Table 2), with VPC confirming appropriate predictions of the 306 
plasma concentration-time profiles for each study (Figure 2). 307 
In non-Caucasian subjects, physiological parameters, such as body-weight, vary significantly 308 
from typical Caucasian subjects and these differences may alter the pharmacokinetics of the 309 
drugs 
46
. We have previously demonstrated the impact of this in Thai 
67,68
, Sudanese and 310 
Papua New Guinea 
68
, Ugandan 
69
 and Malaysians 
70
 population groups, and these alterations 311 
were made to the Simcyp HV population groups (Supplementary Materials: Section B).  312 
Following these revision, in all single and multidose simulations involving Caucasians and 313 
non-Caucasian subjects, plasma concentration-time profiles and resultant pharmacokinetic 314 
parameters were well predicted (Figure 3) and within 2-fold of the reported parameters 315 
(Table 2) 
32,47,71-75
. 316 
Having successfully validated a non-pregnant model in Caucasian and non-Caucasian 317 
subjects, the model was extended to pregnancy subjects. The non-pregnant model was 318 
adapted by the inclusion of a full PBPK distribution model, which enables the consideration 319 
of gestational-age related alterations in maternal physiology.  This is important considering 320 
that physiological alterations such as blood volume, tissue perfusion, plasma protein binding 321 
41,42,44,45
 and CYP450 metabolic capacity 
43
 can occur.  One strength of PBPK modelling is in 322 
its ability to incorporate these changes into predictive modelling approaches 
38
.  When using 323 
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this pregnancy model, key pharmacokinetic parameters were predicted to within 2-fold of the 324 
reported clinical parameters (Table 2), with plasma concentration-time profiles well 325 
recovered for all studies (Figure 4) 
31,32,47
.  The altered blood volumes, blood flows and 326 
albumin binding capacity expected in pregnancy led to a reduction in the overall exposure of 327 
CQ in pregnant subjects compared to non-pregnant subjects (Table 2), and a similar decrease 328 
in exposure (AUC) and associated Cmax has been reported in studies where was used in 329 
pregnant subjects 
31,32,47
. 330 
Current dose regimens for CQ use in antimalarial prophylaxis, RA and SLE treatment were 331 
next examined to determine the ability of these regimens to drive steady state concentrations 332 
within the proposed therapeutic window for ZIKV disease. With a malaria prophylactic 333 
weekly CQ dose of 150 mg and 300 mg administered to pregnant subjects during the first 334 
trimester, the proposed therapeutic range for ZIKV was not achieved (Supplementary 335 
Materials: Section C Figure S3).   However, when CQ doses commonly used for SLE, that is, 336 
150 mg daily (Figure 5A) or 300 mg daily (Figure 5B) was administered, the 150 mg daily 337 
dose achieved a satisfactory mean steady-state Cmax (Table 3) within the proposed therapeutic 338 
window for ZIKV (Figure 5A), and attained the lower th rapeutic window on day 12 (Table 339 
3). However, despite the higher daily dose of 300 mg achieving the target lower therapeutic 340 
limit after 5 days, this regimen was not selected as a result of peak plasma concentrations 341 
exceeding the upper therapeutic window (Figure 5B) (Table 3).    342 
Based upon the 150 mg daily dose regimen, an optimal dosing regimen was derived to reduce 343 
the time taken for trough concentration of CQ to fall within the therapeutic range proposed, 344 
and consist of: (i) an initial loading dose of 600 mg on day 1; (ii) 300 mg daily on day 2 an 3; 345 
(iii) 150 mg daily thereafter (Figure 5C).  This dosing regimen attained the target lower limit 346 
within 6 days with the majority of subjects, 96 %, possessing trough plasma concentrations 347 
within above the lower therapeutic window (Table 3). In order to improve the clinical 348 
Page 18 of 65Journal of Pharmaceutical Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
plausibility of the optimised dose, the optimised dose was adapted from doses used for 349 
malaria treatment (600mg at 0 hour, 6 hours, 24 hours and 36 hours) 
71-74
 and SLE/RA 350 
prophylaxis (long-term 150 mg daily dose) 
18
 because there is sufficient evidence to show at 351 
these doses, CQ administration is safe for both mother and foetus 
18
 
24
. 352 
Having identified an optimal dosing regimen, we next assessed its application at different 353 
trimesters, and when comparing trimester 1 to trimester 3, identified a concurrent decrease in 354 
Cmax (0.92 ± 0.41 µM to 0.53 ± 0.21 µM) and AUC (21.8 ± 9.6 µM.h to 11.8 ± 4.8 µM.h) 355 
(Table 4) (Figure 6A), which resulted in an increased in the time take to achieve trough 356 
plasma concentrations at the lower limited of the therapeutic window (Figure 6B) (Table 4).   357 
The physiological changes during pregnancy, primarily alterations in the body weight, 358 
plasma proteins and plasma volume 
76-80
, will drive this decrease in exposure as gestation 359 
progresses. 360 
Finally, when assessing the optimised dosing regimen for its use throughout pregnancy, we 361 
first considered dosing through trimester 1 only (Figure 7A), which resulted in mean plasma 362 
concentrations decreasing below the lower window at 150 days gestation (Figure 7A) where 363 
95 % of subjects possessing tough plasma concentrations above the lower window (Table 5).  364 
On extension of this optimised dosing regimen throughout trimester 2 (Figure 7B), mean 365 
plasma concentrations were maintained within the therapeutic window until day 279, which 366 
exceeded the start of the ‘at term’ phase, commencing from week 38 onwards (Figure 7B), 367 
and where 94 % of subjects possessed trough plasma concentrations above the lower 368 
therapeutic window.  369 
In summary, we have identified a possible therapeutic regent that would be capable of 370 
proving sufficient plasma exposure for the duration of the gestations period to potential limit 371 
ZIKV uptake into the developing foetus.  However, this study is not without limitations.  372 
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An obvious limitation to our work is the current inability to accurately predict the 373 
pharmacokinetics of CQ in the foetus. Only two clinical studies have reported CQ as being 374 
able to reach the foetus through sampling cord blood 
26,27
, but foetal drug levels were not 375 
recorded. However, the reported foetal: maternal concentration ratio was reported to be near 376 
unity, suggesting overall foetal exposure would be similar to that within the mother.  377 
Therefore we assumed that the driving force for overall foetal exposure would be the material 378 
plasma concentration, which was used as a measure of the ‘target’ concentration within the 379 
foetus also.  It further goes without saying that this assumption would therefore need to also 380 
consider the gestational-related changes in foetal physiology.  However, the placenta plays a 381 
vital ADME role in controlling delivery of xenobiotics to the foetus, and given the similarity 382 
in exposure of CQ between both the mother and foetus 
26,27
, the Simcyp Pregnancy model 383 
incorporated these key gestation related changes in anthropometric features of the mother 384 
and the foetus (implemented as a pooled feto-placental compartment within Simcyp) 
38-40
. 385 
Recently Abduljalil et al (2018) 
81
 have collated foetal biometry and tissue composition data 386 
which may drive future studies to better describe and drive, from a mechanistic 387 
pharmacokinetic viewpoint, the development of a more appropriate and detailed foetal PBPK 388 
model which could predict overall foetal CQ brain exposure, however without CQ foetal 389 
tissue sampling data, any validation of such prediction would be difficult. 390 
Our modelling approach utilised a ‘worst-case’ scenario in deriving a possible plasma 391 
therapeutic window for CQ.  Our upper and lower plasma concentrations, 2 µM and 0.3 µM 392 
respectively, was based on assuming that a 10-to-30-fold greater brain concentration existing 393 
when compared to plasma concentrations for CQ 
49,50
.  We utilised the average of this range, 394 
a 20-fold lower plasma concentration compared to reported range of inhibitory concentration 395 
of 6-40 µM 
17,48
.  Whilst not being able to directly verify human foetal brain concentrations, 396 
our range of predicted peak plasma concentrations (0.1-1.88 µM) for the final optimised 397 
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dosing regimen in pregnant subjects spanned this range and would potentially provide an 398 
overall peak brain exposure of 18.8 µM to 56.4 µM.  This is assuming that CQ is capable of 399 
partitioning across the blood-brain barrier (BBB), with reports suggesting the BBB does not 400 
provide a permeability barrier to CQ 
50
.  However, it is known that the foetal BBB develops 401 
from gestational week 8 with tight junction formation by week 18 
82
.  Therefore further 402 
characterisation of the role of the foetal BBB is warrented to estimate the likely CQ foetal 403 
brain exposure. 404 
In relation to the dosing regimen proposed, chloroquine has been in use for at least 50 years, 405 
having been introduced as an alternative to quinine 
28,29
.  Its use in pregnancy has therefore 406 
been examined by various groups for safety and efficacy with little reported concerns.  At 407 
doses proposed in this simulation, Klinger et al (2001)
83
 reported no ophthalmic 408 
abnormalities in children born followed the maternal use of CQ during a mean duration of 7.2 409 
months of gestation for doses of up to 332 mg daily. In a further study by Rukaria-410 
Kaumbutho et al (1996)
84
, at doses of 25 mg/kg over 3 days, no safety concerns were 411 
identified in births at term.  Further, a review by Nosten et al (2006) 
85
 identified 755 cases of 412 
first trimester exposure to chloroquine with no significant abortion risk or foetal risk.  Finally, 413 
a study by Wolfe and Cordero (1985) 
24
 examined a cohort of 168 births to women treated 414 
with 300 mg CQ once weekly during the duration of pregnancy and identified no significant 415 
increase in the proportion of birth defects when compared to a control group who were not 416 
treated with CQ.  Therefore, the proposed dosing regimen would provide a level of exposure 417 
similar to those reported in existing studies of CQ in pregnant women. 418 
5. CONCLUSION 419 
With the CQ model developed in this study, a CQ dose of 600 mg on day one, followed by 2 420 
days treatment of 300 mg daily and thereafter 150 mg daily from day 3 until the end of 421 
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trimester 2 would provide a plasma concentration within the range of 0.3-2 µM, potentially 422 
providing protection against ZIKV throughout pregnancy.  Though the results from this study 423 
are subject to clinical confirmation, it is serves as a guide for future clinical studies. 424 
  425 
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List Of Figures 687 
Figure 1: Workflow of PBPK model 688 
The workflow based approach implemented in the development and validation of a CQ 689 
model for use in non-pregnant and pregnant subjects.  690 
 691 
Figure 2: Simulated blood or plasma concentration-time profiles of single dose CQ in 692 
non-pregnant subjects 693 
Simulated blood or plasma concentrations for CQ following single dose studies in healthy 694 
Caucasian (Frisk-Holmberg, Gustaffson and Mzayek only) subjects and non-Caucasian 695 
subjects. Solid lines represent mean predicted concentration-time profile with dotted lines 696 
representing 5
th
 and 95
th
  percentile range. Open red circles represent observed clinical data 697 
from each study.  For the Mzayek et al study, red circles indicate data extracted from 698 
complete plasma concentrations profile ‘lines’ for individual subjects rather than discrete 699 
time-points. Where presented, error bars indicate standard deviation.  700 
 701 
Figure 3: Simulated blood or plasma concentration-time profiles of multiple dose CQ in 702 
non-pregnant subjects 703 
Simulated mean blood or plasma concentrations for CQ following multi- dose studies in 704 
healthy Caucasian subjects (Wetsteyn only) and non-Caucasian subjects. Solid lines represent 705 
mean predicted concentration-time profile with dotted lines representing 5
th
 and 95
th
  706 
percentile range. Open red circles represent observed clinical data from each study. Error bars 707 
indicate standard deviation in the Lee; Na-Bangchang; Tanariya; Bustos and Wetsteyn 708 
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studies. Individual plasma or blood concentration data point are represented by open red 709 
circles in Karunajeewa and Hoglund studies.  Left-hand side panels indicate simulations for 710 
the total study duration and right-hand side panels illustrate the first three dosing days.  711 
 712 
Figure 4: Simulated plasma concentration-time profiles of multiple dose CQ in 713 
pregnant subjects 714 
Simulated mean plasma concentrations for CQ following multidose studies in pregnant 715 
subjects. Solid lines represent mean predicted plasma concentration-time profile with dotted 716 
lines representing 5
th
 and 95
th
  percentile range. Open red circles represent observed clinical 717 
data from each study. Error bars indicate standard deviation. Left-hand side panels indicate 718 
simulations for the total study duration and right-hand side panels illustrate the dosing period 719 
only.  720 
 721 
Figure 5:   Simulated plasma concentration-time profiles for CQ dosed during the first 722 
trimester.  723 
Simulated CQ plasma concentration-time profiles during trimester 1 for: (A) a 150 mg daily dose; 724 
(B) a 300 mg daily dose; (C) a proposed optimised daily dose. Dark green lines indicate mean 725 
plasma concentration-time profiles; light green shaded area bordered by the dash lines indicate 726 
the area within the 5th and 95th percentile of predicted mean plasma concentration-time profiles; 727 
light brown shaded area represents the proposed therapeutic range of CQ for ZIKV (0.3-2 µM); 728 
dashed dash vertical lines indicates the time at which trough concentration are maintained above 729 
the lower therapeutic window.  730 
 731 
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Figure 6: Simulated plasma concentration-time profiles for CQ dosed during each trimester 732 
Simulated CQ plasma concentration-time profile utilising the optimised dosing regimen, during 733 
each trimester. (A) Simulated profiles for the entire duration of each trimester; (B) Simulated 734 
profiles for the first 40 days of each trimester. Dark green, red and blue lines indicate mean 735 
plasma concentration-time profiles during the 1st, 2nd and 3rd trimesters respectively; lighter 736 
shaded areas indicate the area within the 95th and 5th percentile of the predicted mean plasma 737 
concentration-time profiles during trimester 1 (upper, light green) and trimester 3 (lower, light 738 
blue); light brown shaded area represents the proposed plasma therapeutic window of CQ for 739 
ZIKV (0.3-2 µM); dashed dash vertical lines indicates the time at which trough concentration are 740 
maintained above the lower therapeutic window.  741 
Figure 7:  Simulated plasma concentration-time profiles for CQ dosed during trimester 1 742 
and 2 743 
Simulated CQ plasma concentration-time profile utilising the optimised dosing regimen during 744 
(A) trimester 1 and (B) throughout trimester 1 and 2.  Left panels indicate the entire duration of 745 
gestation (day 0 to 280) and right panels indicate periods from the end of the trimester to the 746 
point at which mean trough plasma concentrations fall below the lower therapeutic window.  747 
Dark green and blue lines indicate mean plasma concentration-time profiles during the 1st and 2nd 748 
trimesters respectively with lighter shaded areas indicating the area within the 95th and 5th 749 
percentile of the predicted mean plasma concentration-time profiles; light brown shaded area 750 
represent the therapeutic range of CQ proposed to be effective against ZIKV.  The time at which 751 
the mean trough plasma concentrations fall below the lower therapeutic window is indicated by 752 
the arrows.  Red dashed lines indicates the ‘at term’ phase. 753 
 754 
 755 
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Table 1: Model parameter values for base and optimised model of CQ in non-pregnant and pregnant 
subjects 
Parameter 
Optimised model 
(non-pregnant) 
Optimised model 
(pregnant) 
Compound type Diprotic base 
43
 Diprotic base 
43
 
Molecular weight (g/mol) 319.9 
44
 319.9 
44
 
log P  4.72 
45 4.72 45 
fu 0.55
 46
 0.55 
46
 
pKa 1 10.1 
45 10.1 45 
pKa 2 8.38 
45
 8.38 
45
 
Vss (L/kg) 125 (CV: 40 %) 
b
 130
b
 
Vsac (L/kg) 52.9 
b
 - 
Q (L/h) 5 
b
 - 
Kp scalar - 3.35 
c
 
fa 0.8 
d 0.8 d 
ka (h
-1
) 1.2
 d
 0.5 
d
 
Solubility (mg/mL) 0.0175 
44
 0.0175 
44
 
Vmax2D6 (pmol/min/pmol) 2.10 
47
 2.10 
47
 
Vmax3A4 (pmol/min/pmol) 2.94 
47
 2.94 
47
 
Vmax2C8 (pmol/min/pmol) 8.33 
47
 8.33 
47
 
Km2D6 (µM) 19.5 
47 19.5 47 
Km3A4 (µM) 294 
47
 294 
47
 
Km2C8 (µM) 111 
47
 111 
47
 
fumic 0.13
 e
 0.13 
e
 
ISEF CYP 2D6 0.5 
f
 0.8 
f
 
ISEF CYP 3A4 0.42 
f
 0.7 
f
 
ISEF CYP 2C8 1.1 
f 1.6 f 
Clrenal (L/h) 4.6 
g
 5.5 
g
 
Absorption model  first order first order 
Distribution model minimal PBPK full PBPK 
a
 Simcyp® mechanistic prediction; 
b
 parameter estimated using a minimal PBPK model with a single adjusting 
compartment (SAC); 
c
 an appropriate Kp scalar was empirically optimised for a full PBPK model in 
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pregnancy; 
d
 parameter estimated using a first order absorption kinetic model; 
e
 parameter estimated; 
f
 
parameter estimated for use in optimisation of clearance kinetics; 
g
 parameter estimated. logP: the logarithm 
of the n-octanol:buffer partition coefficient; fu: unbound fraction; B/P: blood-to-plasma ratio; Vss: steady 
state volume of distribution; Vsac: volume of single adjusting compartment; Q: blood flow to the single 
adjusting compartment; ka: absorption rate constant; Kp scalar: scalar applied to all predicted tissue partition 
values fa: fraction dose absorbed; ka: absorption rate constant; Vmax: maximum rate of metabolite 
formation; Km: Michaelis-Menten constant; fumic: fraction of unbound drug in the invitro microsomal 
incubation; ISEF: Intersystem extrapolation factor for scaling CYP in-vitro kinetic data; CLrenal: renal 
clearance.  
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Table 2. Summary of predicted and observed pharmacokinetic parameters of for CQ 
    Cmax tmax (h) AUC 
    Predicted Observed Predicted Observed Predicted Observed 
C
a
u
c
a
s
i
a
n
 
S
i
n
g
l
e
 
D
o
s
e
 
Gustafsson  
a,  e
 56.8 ± 23.8 76 ± 14 4.9 ± 2.6 3.6 ± 2.0 9315 ± 3951 6111 ± 1315 
Mzayek 
 b, f *
 1.45 (0.3 – 6.1) 1.8 (1.3-5.2) 4.2 (1.5 – 7.1) 3.0 (1.0-8.0) 112 (31.5 - 225) 90 (48.9-212 
Frisk (150 mg dose)
 b,  i
 0.11 NR 5.2 ± 2.4 NR 3.14 ± 1.3 2.54 ± 0.55 
Frisk (300 mg dose)
 b,  i
 0.94 NR 5.2 ± 2.4 NR 6.28 ± 2.5 6.19 ± 1.39 
Frisk (600 mg dose)
 b, i
 1.9 ± 7.4 NR 5.2 ± 2.4 NR 12.6 ± 5.1 11.6 ± 2.4 
N
o
n
-
C
a
u
c
a
s
i
a
n
 
S
i
n
g
l
e
 
D
o
s
e
 
Chukwuani 
 a, e
 177 ± 170 391 ± 91 4.7 ± 2.4 5.6 ± 0.8 7408 ± 4622 10820 ± 2714 
Najmi 
 c, g,
** 172 ± 166 201 ± 15 4.6 ± 2.3 6.10 ± 0.66 12775 ± 5835 10827 ± 1340 
Walker 
 a, e
 159 ± 149 374 ± 56 4.8 ± 2.4 5 ± 3 25865 ± 10608 18609 ± 4254 
N
o
n
-
C
a
u
c
a
s
i
a
n
 
M
u
l
t
i
 
D
o
s
e
 
 
Karunajeewa 
 c, g,
** 297 (79.1-769) 376 
#
 - - 
57014 (11218-
112760) 
47892 (43486-
53746) 
Na-Bangchang 
 a,  j.***
 883.6 (266-2306) 838 (656-1587) - - 167 (35.4-315) 122 (103-182) 
Bustos 
 a,  k,** 166.4 (63.47-335.7) 285 (186-422) - - 2189  (525-4760) 2299 (1149 -39908) 
Lee 
 a, e,
** 836 (244-3006) 700 (403 - 1625)
##
 - - 
189024               
(47160 - 334210) 
134087 (62940 - 
229695) 
Hoglund 
 b, I,**
 2.7 (2.04) NR 3.8 NR 24.2 (10.3) NR 
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Tanariya 
 a, k,**
 994 (666) NR 4.3 NR 7897 (3245) NR 
C
a
u
c
a
s
i
a
n
 
 
M
u
l
t
i
 
D
o
s
e
 
Wetsteyn 
 d, l,**
 85.6 (56.1) NR 3.6 NR 1429 (590) NR 
 
P
r
e
g
n
a
n
t
 
Fakeye 
 a, e
 123.9 ± 56.0 204.36 ± 134.7 4.6 ± 1.68 2 2113.9 ± 38.3 NR 
Karunjeewa 
 d, h,**
 145.7 (53.4-240.5) 296** - - 
38585               
(14236-65641) 
35750 (31343-
39729) 
Lee 
 a, e,**
 482.7 (166.5-921.8) 960.5 (297-1835) 3.84 (2.4- 4.8) 3 (1.5- 8) 
156 847               
(54768-349488) 
122216 (74145- 
269600) 
 
Units for Cmax are as follows: 
a
 ng/mL; 
b
 µM; 
c
 mg/L; 
d
 µg/L; Units for AUC are as follows: 
e
 ng/mL.h; 
f
 µM.h; 
g
 mg/L.h; 
h
 µg/L.h; 
i
 µM.day; 
j
 
µg/mL.h ; 
k
 ng/mL.Day; 
l
 µg/L.Day. Unless otherwise stated, data represent means ± SD or median (range). * Data represents median (range); ** 
AUC0-∞ (AUC calculated from the start of the study and extrapolated to infinity); *** AUC0-28d: AUC calculated 28 days period only; **** AUC0-48d: 
AUC calculated 48 days period only. 
#
 No SD or median was reported; 
##
 Cmax reported for the first dose only 
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Table 3: Steady-state pharmacokinetic parameters of CQ during pregnancy 
Dose  
(mg) 
Cmax 
(µM) 
tmax  
(h) 
AUC  
(µM.h) 
Time to 
lower 
window 
a
 
(days) 
Percentage of 
subjects with 
Cmin > 0.3 µM 
at SS 
b
 
Percentage 
of subjects 
with Cmax < 
2 µM at SS 
c
 
150 0.9 ± 0.4 2.4 ± 0.5 21.8 ± 9.4 12 96 99 
300 1.8 ± 0.8 2.4 ± 0.5 43.9 ± 18.7 5 99 59 
Optimised 0.9 ± 0.4 2.4 ± 0.5 48.8 ± 30.9 6 96 99 
Data represents mean ± standard deviation. 
a
 Time taken for mean trough plasma 
concentrations to be maintained above 0.3 µM; 
b 
Percentage of subjects with trough plasma 
concentrations above 0.3 µM at steady-state; 
c 
Percentage of subjects with peak plasma 
concentrations below 2 µM at steady-state.  AUC was calculated for the final dosing day.   
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Table 4: Steady-state pharmacokinetic parameters of the optimised CQ regimen 
during pregnancy 
Trimester 
Cmax  
(µM) 
tmax  
(h) 
AUC  
(µM.h) 
Time to 
lower 
window 
a
 
(days) 
Percentage of 
subjects with 
Cmin > 0.3 
µM at SS 
b
 
Percentage of 
subjects with 
Cmax < 2 µM 
at SS 
b
 
1 0.92 ± 0.41 2.2 ± 0.5 21.8 ± 9.6 6 96 99 
2 0.75 ± 0.32 2.2 ± 0.5 17 ± 7.2 14 93 100 
3 0.53 ± 0.21 2.6 ± 0.7 11.8 ± 4.8 35 79 100 
Data represents mean ± standard deviation. 
a
 Time taken for mean trough plasma 
concentrations to be maintained above 0.3 µM; 
b 
Percentage of subjects with trough plasma 
concentrations above 0.3 µM at steady-state; 
c 
Percentage of subjects with peak plasma 
concentrations below 2 µM at steady-state.  AUC was calculated for the final dosing day. 
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Table 5: Steady-state pharmacokinetic parameters of the optimised CQ regimen 
during pregnancy 
  Trimester 
  1 1 and 2 
*
 
Cmax  (µM) 0.92 ± 0.41 0.92 ± 0.41 
tmax (h) 2.2 ± 0.5 2.2 ± 0.5 
AUC (µM.h)  20.9 ± 9.6 21.0 ± 9.5 
Time to increase to lower window 
a
 (Days) 6 6 
Subjects with Cmin above window (%) 
b
 67 65 
Time to decrease to lower window
 c
 (Days) 150 279 
Subjects with Cmin above window (%) 
b
 95 94 
Subjects with Cmax below window (%) 
d
 1 5 
 
Data represents mean ± standard deviation from the final dose. * Cmax, tmax and AUC 
collected on the final dosing day.  
a
 Time taken for mean concentrations to be reach 0.3 µM; 
b 
Percentage of subjects with trough plasma concentrations above 0.3 µM; AUC was calculated 
for the final dosing day; 
c 
Time taken for mean plasma concentrations to decrease to 0.3 µM; 
d 
Percentage of subjects with peak plasma concentrations below 0.3 µM. 
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Dose optimisation of chloroquine by pharmacokinetic modelling during 1 
pregnancy for the treatment of Zika virus infection 2 
Olusola Olafuyi1 and Raj K. S. Badhan1,2  3 
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Section A 6 
Table S1.  Summary of single and multiple dose studies used in the validation of CQ pharmacokinetics in non-pregnant subjects 7 
Study 
Number 
of 
subjects 
Ethnic group Age (Years) 
Weight  
(kg) 
Gender 
 (M/F) Dosing regimen 
Concentration 
matrix 
Mzayek et al (2007)1 24 
Mixed  
(Caucasian  
and  
Black American) 
28.7 ± 5.3 75.8 ± 18.6 M, F 600 mg (single 
oral) Blood 
Gustaffson et al 
(1983)2 11 Caucasian 20 - 36 65 - 91  M 
300 mg (single 
oral) Plasma 
Najmi et al (2008)3 10 Pakistani 33.5 66 M 600 mg (single 
oral) Plasma 
Höglund et al (2016)4 75 Thai 17 - 52 NR M, F 
10 and 5 mg/kg at 0 
and 6–12 h on day 
0, and 5 mg/kg each 
on day 1 and day 2 
Plasma 
Karunajeewa et al 
(2010)5 30 Papuan 25.5 ± 8.9 51.8 ± 5.5 F 
450 mg once daily 
for 3 days  Plasma 
Tanariya et al (1995)6 57 Thai 26.4 ± 8.7 56.4 ± 7.1 M, F 
600 mg initially, 
followed by 300 mg 
at hours 6, 24 and 
48 hours) 
Blood 
Na-Bangchang et al 
(1994)7 7 Thai 18 - 35 45 - 68 M 
600 mg initially, 
followed by 300 mg 
at hours 6, 24 and 
48 hours) 
Blood 
Chukwuani et al 
(2004)8 5 Nigerian 23 - 37 56 - 66 F 
600 mg (single 
oral) Plasma 
Lee et al (2008)9 13 Thai 29 (15 - 40) 46 ± 4.9  F 
10, 10, and 5 mg/kg 
given at 0, 24, and Blood 
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48 hours 
Bustos et al (2002)10 11 Filipino 35 (13 - 63) 60 (40-63) M, F 
10 and 5 mg/kg at 0 
and 6 hours on day 
0, and 5 mg/kg each 
on day 1 and day 2 
Plasma 
Wetsteyn et al 
(1995)11 5 Caucasian 41 64 ± 10 M, F 
300 mg weekly for 
3 weeks  Plasma 
Frisk-Holmberg et al 
(1984)12 5 Caucasian 37 - 42  72 ± 8 M, F 
150 mg (single 
oral); 300 mg 
(single oral); 600 
mg (single oral) 
given to each 
subject on 3 
separate occasions 
Blood 
Walker et al (1987)11  8 Nigerian 19 - 55 53 - 66 M, F 600 mg (single 
oral) Plasma 
 8 
Data represented as: range, mean (range) or mean ± SD. 9 
 10 
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Section B 11 
Step 1: Development and validation of a CQ model in non-pregnant subjects 12 
In this step, the CQ model was optimised to adequately recover the general shape of 13 
the plasma concentration-time profiles and accurately predict pharmacokinetic 14 
parameters of CQ in non-pregnant populations. Where the initial model did not 15 
appropriately recover pharmacokinetic phases and parameters, a parameter estimation 16 
methodology was employed.   17 
To recover the shape of the absorption phase, a First Order absorption model was 18 
utilised to identify an appropriate maximum plasma/blood concentrations (Cmax) and 19 
time to reach the Cmax (tmax).  Clinically reported absorption rate constants (ka) and 20 
fraction absorbed (fa) values were selected with ka reported in literature as ranging 21 
from 0.27 to 3.4 h-1 and fa reported as 0.9.  These were empirically fixed (with ka 22 
fixed as the mean of the reported range), and subsequently optimised by parameter 23 
estimation methodology implementing a Weighted Least Square (WLS) approach and 24 
the Nelder-Mead minimisation method to arrive at parameters which appropriately 25 
recovered the absorption phase (fa: 0.8; ka: 1.2 h-1), and were within the range 26 
reported from clinical studies 13-15. 27 
The volume of distribution at steady-state (Vss) was estimated by a similar 28 
methodology as that applied for the absorption phase, with Vss reported in clinical 29 
studies as ranging from 100 L/kg to 1000 L/kg 5,16,17, and empirically fixed as the 30 
mean of this range prior to parameter estimation.  As the reported Vss was large, a 31 
minimal PBPK model was utilised with the incorporation of a ‘single adjusting 32 
compartment’ (SAC) to capture the correct distribution phases of the plasma 33 
concentration-time profile (Figure S1).  Final parameter estimates of 125 L/kg for the 34 
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central compartment (VSS) and 52.9 L/kg for the SAC (Vsac) were able to appropriately 35 
recover the distribution phase of the profile.  It should be noted that this was achieved 36 
following the incorporation of a change in the mean dispersion parameter applied to 37 
the central compartment (i.e. the coefficient of variation), which was adjusted from 38 
the Simcyp default of 30 % to a revised 40 %. 39 
Finally, the rate of metabolite formation, Vmax and Michaelis-Menten constant (Km) 40 
for CYP2D6, 3A4 and 2C8 elimination pathways were obtained from a literature 41 
reported study 18 using recombinant P450 systems.  However, to achieve satisfactory 42 
recovery of the elimination phase, the Inter-System Extrapolation Factor (ISEF) for 43 
scaling recombinant cytochrome (CYP) P450 enzymes from in vitro kinetic data were 44 
parameter estimated for all three metabolism pathways. In addition, CQ elimination 45 
has contributions from both hepatic and renal pathways, with the latter contribution 46 
approximately 30-50 % of the total clearance of CQ 2,19.  Therefore, a renal clearance 47 
was parameter estimated based on an empirically fixed mean estimate. 48 
Parameter sensitivity analysis was subsequently conducted on ISEF for CYP2D6 and 49 
CYP3A4 (the two isozymes requiring significant changes in ISEF).  When conducted 50 
over a range of 0.2-2, there was minimal sensitivity of CL, Cmax and AUC to changes 51 
in ISEF (Figure S2) confirming appropriate estimates of ISEF for CYP2D6 and 52 
CYP3A4.  53 
These revisions were confirmed in against 13 published clinical studies conducted in 54 
Caucasian and non-Caucasian subjects. Final parameter estimates are detailed within 55 
Table of the manuscript.  56 
  57 
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All modelled was conducted within the Simcyp Simulator (Version 17).  This is 58 
available under a free licence for academic research (non-profit) from Certara 59 
(www.certata.com).  However, for those unable to obtain a licence from Certara, the 60 
open source package PK-Sim (Open Systems Pharmacology) 61 
(https://github.com/Open-Systems-Pharmacology) allows simulations in both non-62 
pregnant and pregnant subjects and provides a detailed summary of ‘systems’ related 63 
parameters for model building.    The ‘Compound’ related parameters described 64 
within Table 1 of the manuscript will allow re-creation and re-validation of CQ within 65 
PK-SIM.66 
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 67 
Figure S1:   PBPK models utilised within Simcyp.  68 
Structure of the full (A) and minimal (B) PBPK models used within the Simcyp Simulator. Q refers to tissue perfusion; Kin/Kout (CLint/CLout): refer to 69 
transfer processes between the systemic compartment and the single adjusting compartment.  70 
 71 
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  72 
Figure S2:   Sensitivity analysis of CYP3A4 and CYP2D6 ISEF 73 
Sensitivity analysis of (A) clearance, (B) first dose Cmax and (C) AUC following 74 
alterations in CYP3A4 and CYP2D6 ISEF (over a range of 0.2-2) for non-pregnant 75 
adults. Current optimised model estimates (CYP3A4 ISEF = 0.42 and CYP2D6 = 0.5) 76 
and default estimates (ISEF = 1) are illustrated. 77 
  78 
Page 58 of 65Journal of Pharmaceutical Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
9 
 
Adaptation of the age-weight relationships for non-Caucasian groups  79 
Customised age-weight relationships for non-Caucasian subjects were incorporated 80 
through adaptation of the Simcyp Healthy Volunteer population group and utilising 81 
reported age-weight relationships 20 for specific countries of origin relating to each 82 
clinical study used, which included Filipinos, Nigerians, Pakistani, Papuans and 83 
Thais. The reported median age-weight reference charts for the specific population 84 
groups were used to establish mathematical (polynomial regression) relationships to 85 
predict body weight from age, using TableCurve2D (Systat Software, San Jose, CA, 86 
USA) 87 
The final mathematical relationships are detailed below: 88 
Filipinos and Papuans 89 
Due to geographical locations, an age-weight relationship for Filipinos and Papuans 90 
were assumed to be similar and the age weight relationship was shown below: 91 
Adult males: 92 
Body weight = (6.0000871 + (1.8363904*age) + (-0.28876641*age2) + 93 
(0.011482471*age3)) / (1 + (-0.06584622*age) + (-0.0016572488*age2) + 94 
(0.00016955778*age3)) 95 
 96 
Adult females: 97 
Body weight = (6.03 + 0.197*age2 + 0.0012*age4) / (1+0.00127*age2 + 98 
0.0000255*age4) 99 
 100 
 101 
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Nigerians:  102 
Adult males: 103 
Body weight = (3.1190351 + (2.7547707*age0.5)+(-104 
1.9861521*age)+(0.29731577*age1.5))/(1+(-105 
0.63494158*age0.5)+(0.15239313*age)+(-106 
0.017751472*age1.5)+(0.0010549434*age2)) 107 
Adult females:  108 
Body weight = (3.9015149+(0.280026178*age0.5) + (-0.92347063*age) + 109 
(0.16145376*age1.5)) / (1 + (-0.75349793*age0.5) + (0.2157188*age) + (-110 
0.028738874*age1.5) + (0.0016167479*age2)) 111 
 112 
Pakistani and Thais: 113 
Due to geographical locations, an age-weight relationship for Pakistani and Thais 114 
were assumed to be similar and the age weight relationship was shown below: 115 
Adult males:  116 
Body weight = 33.46 + (-0.3569*age2) + (0.001522*age4) / (1 + (-0.00755*age2) + 117 
(2.78x10 - 5*age4) + (-1.07x10-9*age6)) 118 
Adult Females: 119 
Body weight = -920.66 + (-188.63*age) + (22.48*age1.5) + (-0.999*age2) + 120 
(700.23*age0.5).  121 
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Section C 122 
Table S2.  Summary 123 
of single and 124 
multiple dose 125 
studies used in the 126 
validation of CQ 127 
pharmacokinetics in 128 
pregnant subjects 129 
 130 
 131 
 132 
 133 
 134 
Study 
Number 
of 
subjects 
Ethnic 
group 
Age  
(Years) 
Weight 
(kg) 
Gestation  
(Weeks) 
Dosing 
 regimen 
Concentration 
matrix 
Karunajeewa et 
al 20105 30 Papuan 26.0 ± 5.9 54.0 ± 6.4 NR 
450 mg once daily 
for 3 days  Plasma 
Lee et al 
20089 12 Thai 25 (15 - 37) 49.5 ± 5.6 20 -32 
10, 10, and 
5 mg/kg  given at 
0, 24, and 48 hours 
Blood 
Fakeye et al, 
200221 4 Nigerian 30 ± 2.3 60.3 ± 8.9  
10, 10, and 
5 mg/kg  given at 
0, 24, and 48 hours 
Plasma 
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Data represented as: range, mean (range) or mean ± SD. 135 
 136 
 137 
 138 
 139 
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 140 
Figure S3:   Simulated plasma concentration-time profiles for CQ dosed once 141 
weekly during the first trimester.  142 
Simulated CQ plasma concentration-time profiles during trimester 1 for: (A) a 150 mg 143 
weekly dose; (B) a 300 mg weekly dose. Dark green lines indicate mean plasma 144 
concentration-time profiles; light green shaded area bordered by the dash lines indicate 145 
the area within the 5th and 95th percentile of predicted mean plasma concentration-time 146 
profiles; light brown shaded area represents the proposed therapeutic range of CQ for 147 
ZIKV (0.3-2 µM).  148 
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